Exabis Library
Welcome to the e-CCO Library!
P557: Robotic surgery significantly improves outcomes for patients with inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P557: Sustained remission in inflammatory bowel disease patients after discontinuing infliximab; the ongoing reluctance to stop biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P557: Utility of “trough levels” adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic model
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P558 Validation of the ‘IBD Disk’ in clinical practice
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P558: Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P558: Golimumab improves patient-reported work productivity and activity impairment in patients with ulcerative colitis: Interim results from a non-interventional trial in Germany
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P558: Iterative ileocolonic resection for Crohn’s disease: a prospective multi-centric cohort study of the GETAID Chirurgie
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P558: Medication Preference of 400 patients with mild to moderate Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P558: Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P558: The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P559 Effect of vedolizumab and ustekinumab on articular manifestations in patients with inflammatory bowel disease refractory or intolerant to anti-TNF therapy: An observational prospective study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P559: Cannabis Improves Sleep Quality in Patients with Inflammatory Bowel Diseases in a Prospective Observational Study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P559: Efficacy of Ustekinumab in the treatment of patients with Crohn’s disease with failure to previous conventional or biologic therapy: an observational real-life study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P559: Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P559: SARS-CoV-2 vaccination does not increase the risk for flares in Inflammatory Bowel Disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P559: Tacrolimus as a topical therapy for perianal Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P559: Treatment goals in IBD: a perspective from patients and their partners
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P560 Incidence of joint symptoms in patients with inflammatory bowel disease on treatment with vedolizumab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P560: Application of a clinical decision support tool for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicenter study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P560: Clinical outcomes of vedolizumab maintenance treatment for Korean patients with inflammatory bowel disease who failed anti-TNF therapy: A KASID prospective multicenter cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM